WU-CART-007 Receives FDA Breakthrough Therapy Designation for Relapsed T-Cell Leukemia and Lymphoma

On January 21, 2026, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to soficabtagene geleucel (sofi-cel; WU-CART-007), an investigational allogeneic CAR-T cell therapy developed by Wugen Inc. The designation covers treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in pediatric and adult patients.

The therapy uses an off-the-shelf manufacturing model, meaning it is made from donor cells in advance rather than from a patient's own cells. This distinction has meaningful implications for access, speed, and cost. A pivotal Phase 2 clinical trial, designated T-RRex (NCT06514794), is actively enrolling patients.

What T-Cell ALL and T-Cell Lymphoblastic Lymphoma Are

T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are rare, aggressive blood cancers that arise from immature T-cells in the bone marrow or lymphatic system. They are most common in children, adolescents, and young adults, though they can occur at any age. Together, T-ALL and T-LBL account for roughly 25% of all acute lymphoblastic leukemia cases.

When diagnosed at first presentation, the prognosis with intensive chemotherapy is meaningful. The problem is relapse. When T-ALL or T-LBL returns after treatment, or when a patient's disease does not respond to initial therapy at all, outcomes become significantly more difficult.

What Allogeneic Means, and Why It Matters for Patients

Most currently approved CAR-T therapies are autologous, meaning they are made from a patient's own cells. The process can take three to six weeks. For a patient with rapidly progressing disease, that timeline can be the difference between being eligible for treatment and not.

WU-CART-007 is allogeneic, meaning it is made from donor cells and manufactured in advance in large batches. This "off-the-shelf" model means the therapy can potentially be available within days rather than weeks once a decision to treat is made.

How to Access WU-CART-007 Now: The T-RRex Trial

The pivotal Phase 2 clinical trial evaluating WU-CART-007 is called T-RRex. It is registered at ClinicalTrials.gov under identifier NCT06514794 and is currently recruiting pediatric and adult patients with relapsed or refractory T-ALL or T-LBL.

Participating sites include major academic cancer centers. MD Anderson Cancer Center and Cincinnati Children's Hospital Medical Center are among the institutions running the trial. If you or someone you care for has a diagnosis of relapsed or refractory T-ALL or T-LBL, the most direct path to access is to contact a trial site directly or ask your oncologist to evaluate eligibility.

Ellen can help you understand clinical trial options and navigate trial enrollment for experimental therapies. Start here →